Search clinical trials for: MEDI-528 3 mg/kg

Total 1543 results

MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Healthy

United States
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma

Asthma

Canada
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Motavizumab Administration for a Second Season for RSV Prophylaxis

Chile, Brazil
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
MedImmune LLC

Completed

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

Cancer

France
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
AstraZeneca
MedImmune LLC

Terminated

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

Pain | Osteoarthritis

United Kingdom
Sameem M. Abedin, MD

Recruiting

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

Graft-versus-host Disease

United States
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Asthma

United States, Canada
aTyr Pharma, Inc.
Kyorin Pharmaceutical Co.,Ltd

Recruiting

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

United States, Netherlands, Spain, United Kingdom, France, Italy, Brazil, Germany, Puerto Rico, Japan
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
Ludwig Institute for Cancer Research
Daiichi Sankyo Co., Ltd.; Austin Health

Completed

Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers (LUD2014-002)

Malignant Solid Tumor | Metastatic EphA2 Positive Cancer

Australia
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Viridian Therapeutics, Inc.

Recruiting

A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Thyroid Eye Disease

United States
MedImmune LLC

Withdrawn

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

Wheezing
aTyr Pharma, Inc.

Completed

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

SARS-CoV-2 (COVID-19) Severe Pneumonia

United States, Puerto Rico
GlaxoSmithKline

Completed

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) (DMD114876)

Muscular Dystrophies

United States
Alopexx Pharmaceuticals, LLC

Terminated

Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males

Neisseria Gonorrhoeae

United States
Alexion Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD) | LAL-Deficiency

France, United States, United Kingdom, Czechia
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Merck KGaA, Darmstadt, Germany

Completed

Phase I/Ib Multiple Ascending Dose Study in China

Metastatic Solid Tumors

China
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
MedImmune LLC

Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing Forms

United States, Spain, Poland, Ukraine
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
MedImmune LLC

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Respiratory Syncytial Virus Infections

United States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...
MedImmune LLC

Completed

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Malignant Melanoma

United States
MedImmune LLC

Completed

Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

Respiratory Syncytial Virus Infections

Chile, Argentina
MedImmune LLC

Completed

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Psoriasis

United States, Canada
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
MedImmune LLC

Completed

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

RSV Illness in ≤12 Months of Participants

United States, Chile, New Zealand, Australia, Panama
MedImmune LLC

Completed

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Cancer

United States
Chimerix

Terminated

Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

Protein Losing Enteropathy

United States
MedImmune LLC

Completed

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

Healthy

United States
MedImmune LLC

Terminated

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Participants Less Than 12 Months of Age With RSV Illness

United States
MedImmune LLC

Completed

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

United States, France, Spain, Canada, Turkey, Israel, Germany, Russian Federation, Czechia, Hungary, Poland
Rockefeller University
Brigham and Women's Hospital; Weill Medical College of Cornell University; University...

Completed

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

Healthy | HIV

United States, Germany
MedImmune LLC

Completed

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

Respiratory Syncytial Virus Prophylaxis
MedImmune LLC

Completed

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Takeda

Completed

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of

3

Subscribe